Autolus Therapeutics plc

Contributing Author

Recent Articles by Autolus Therapeutics plc

Aug-12	Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates AUTL GlobeNewswire
Jul-24	Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 AUTL GlobeNewswire
Jul-21	Autolus Therapeutics' CAR T Therapy AUCATZYL (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) AUTL GlobeNewswire
Jul-15	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL GlobeNewswire
Jun-12	Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress AUTL GlobeNewswire
May-29	Autolus Therapeutics to Participate in Upcoming Investor Conferences AUTL GlobeNewswire
May-23	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) AUTL GlobeNewswire
May-14	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress AUTL GlobeNewswire
May-08	Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates AUTL GlobeNewswire